Navigating the 2025 Practice Parameter for Inborn Errors of Immunity

The update changes the document’s structure: instead of organizing recommendations primarily around individual genetic conditions, it separates guidance into two broad clinical pathways—diagnosis and management. For families and clinicians, that makes the parameter more useful as a route map through testing, treatment decisions, and longer-term follow-up.

A broader diagnostic pathway

The diagnostic section addresses several stages that can shape the clinical presentation of childhood immunodeficiency. It includes newborn screening for severe combined immunodeficiency, genetic testing, surveillance for comorbidities, and clinically available immunologic testing.

This structure reflects the reality of IEI care: diagnosis is rarely a single laboratory result. The appropriate work-up may involve immune-system testing alongside genetic evaluation and ongoing monitoring for associated health problems. For parents, the practical question is not simply whether a child has “low immunity,” but which part of the immune cascade may be affected, what testing is clinically available, and how the findings will change the management pathway.

The inclusion of newborn screening for severe combined immunodeficiency is particularly relevant to early recognition. However, the evidence provided for this update does not specify changes to screening programmes, eligibility criteria, or testing thresholds. Those details will therefore need to be confirmed in the full parameter and within the healthcare system where a child is being assessed.

Treatment is presented as a coordinated plan

The management section covers immunoglobulin replacement, antibiotic prophylaxis, hematopoietic stem cell transplantation, precision medicine, and quality-of-life assessment. These are not interchangeable options, and the revised format should be read as a framework for matching treatment intensity to the child’s immune defect and clinical needs.

For families already considering immunoglobulin replacement or preventive antibiotics, the important point is that these interventions appear within a wider management pathway rather than as isolated prescriptions. A clinical team may need to consider the suspected or confirmed IEI, infection history, available immune testing, genetic findings, and the child’s response to treatment before deciding what support is appropriate.

Hematopoietic stem cell transplantation and precision medicine also sit within this broader decision-making framework. The available information does not state which genetic conditions are addressed by particular recommendations, nor does it provide outcome data, eligibility rules, or comparative risks. We should therefore avoid treating the update as a universal treatment protocol. It is better understood as an organized set of recommendations to support specialist assessment.

What families should clarify at the next appointment

The 2025 update gives clinicians and families several useful points to discuss:

• Which diagnostic tests are being considered, including immunologic and genetic testing?
• Is newborn screening relevant to the child’s clinical history or current evaluation?
• What comorbidities require surveillance?
• If infections remain a concern, where do immunoglobulin replacement or antibiotic prophylaxis fit in the plan?
• If a severe or defined genetic IEI is suspected, should hematopoietic stem cell transplantation or precision medicine be discussed?
• How will treatment affect daily functioning and quality of life, not only infection frequency?

The published summary does not provide disease-specific recommendations or individual risk estimates, so decisions still require review by an immunology team familiar with IEI. The most meaningful change is the parameter’s practical organization: diagnosis and management are brought together in a way that can help clinicians move from recognizing a possible inborn error of immunity to confirming the diagnosis, selecting appropriate treatment, and maintaining structured long-term follow-up.